Media headlines about Novartis AG (NYSE:NVS) have trended positive on Thursday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis AG earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.494972535589 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Novartis (NVS) Receives EC Nod for Tasigna Label Expansion … – Nasdaq (nasdaq.com)
- Novartis Secures EU Approval for Tasigna Treatment in Children (ih.advfn.com)
- Contrasting Novartis AG (NVS) & Its Competitors (americanbankingnews.com)
- Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy – Investorplace.com (investorplace.com)
- Novartis AG (NVS) versus Cambrex Corporation (CBM) Head to Head Survey (americanbankingnews.com)
Shares of Novartis AG (NYSE:NVS) traded up $0.20 during mid-day trading on Thursday, reaching $84.48. The company had a trading volume of 1,540,300 shares, compared to its average volume of 2,325,532. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90. The company has a market capitalization of $199,372.34, a PE ratio of 17.74, a PEG ratio of 2.69 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81.
NVS has been the topic of several analyst reports. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. BidaskClub cut Novartis AG from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Cowen and Company set a $90.00 target price on Novartis AG and gave the company a “hold” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Tuesday, August 29th. Finally, Zacks Investment Research upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a report on Tuesday, September 19th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $85.32.
WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/23/novartis-ag-nvs-earns-media-impact-score-of-0-28.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.